Inhaled antibiotics for the treatment of pneumonia. [Review] 

 -  2019 
<br/><br/>Available online from MWHC library: 1999 - present 
<br/><br/> PURPOSE OF REVIEW: To describe recent developments in trials exploring inhaled antibiotics for treating severe pneumonia.  RECENT FINDINGS: Three recent randomized studies investigated the potential role for aerosolized antibiotics for gram-negative pneumonia in ventilated patients. One single center, nonblinded investigation suggested a benefit with inhaled amikacin for resistant gram-negative infections. However, two multicenter, blinded trials found no benefit to adjunctive nebulized amikacin for severe gram-negative pneumonia.  SUMMARY: Well done clinical trials do not support the routine use of inhaled amikacin for pneumonia in ventilated patients. There may be a potential role for aerosolized antibiotics when other options are limited. 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>1070-5287 
<br/><br/><label>Standard No.: </label>10.1097/MCP.0000000000000557 [doi] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>*Amikacin/ad [Administration & Dosage]<br/>*Anti-Bacterial Agents/ad [Administration & Dosage]<br/>*Pneumonia, Bacterial/dt [Drug Therapy]<br/>*Pneumonia, Ventilator-Associated/dt [Drug Therapy]<br/>Administration, Inhalation<br/>Humans
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Washington Hospital Center
<br/><br/><label>Index Terms--Occupation: </label><br/>Medicine/Pulmonary-Critical Care
<br/><br/><label>Index Terms--Function: </label><br/>Journal Article